knowledge -WSS

knowledge

author：hotspot 2025-09-14 21:59:10 - browse：3

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Has Bernie Sanders reached the limit of his pharma bullying effort?

explore

WSS

Stanford updates investigation of president’s past research

TikTok cracks down on users posting about weight loss drugs

Black vets could get higher VA benefits if race not used in lung test

Celebrate National Dole Whip Day for 3 days this week at Disney

Why some people catch Covid but never get sick

Is it ever OK for doctors to lie to their patients?

knowledge

knowledge

hotspot

Alkermes shareholders re

GSK’s asthma push continues as drug succeeds in Phase 3 trials

At least 13 dead in Texas as scorching temps continue

Man who had jail sentence commuted by Trump arrested again

Medicare proposal to cover medical devices draws a mixed reaction

Welsh Carson private equity firm escapes from FTC antitrust case

Medical leaders decry Supreme Court decision on affirmative action

Trump got a 'target letter.' What is one and what does it mean?

Jerome Adams on the need for new antivirals for Covid

Ebola public health emergency is over, WHO declares

hotspot

Man who had jail sentence commuted by Trump arrested again

Most antidepressants don't work on kids, teens, study finds

Crowdfunding for medical bills sidesteps core problem, author says

Class action alleges UnitedHealth concealed DOJ probe

Resistance to cancer drugs: A new genetic explanation

Plane’s emergency slide plummets from sky, hits Chicago home

focus

leisure time

explore

leisure time